Spotlight on Vaccines: The Path to Commercial Plan Coverage
Following a severe season of respiratory syncytial virus, or RSV, in the U.S., multiple companies have reported that they have promising vaccine candidates for various patient populations in the late-stage clinical trial pipeline. The FDA could approve some of them as early as this year, for what is estimated to be a market worth more […]
How Will the Launch of Humira Biosimilars Impact Patients, Payers and IDNs?
Across indications, biosimilar uptake is rapidly accelerating, with the number of biologics facing biosimilar competition more than doubling by 2026. This year’s impending launch of adalimumab biosimilars will serve as a case study for manufacturers, who will be studying the market’s response. Humira biosimilars have great potential to disrupt immunology market baskets, especially if multiple […]
Market Access 101: Improving Your Drug’s Formulary Placement
Welcome back to MMIT’s Market Access 101 series, in which we unpack the complexities of market access via a series of blog posts. In our first post, Understanding the Basics, we covered the difference between the pharmacy and medical benefit structure, the typical timeline for drug review, and why it’s critical to determine which entity […]
The Evolution of Medical Benefit Contracting: How Pharma Can Prepare
This article was originally published in Drug Channels. Given the growth of specialty pharmaceuticals, manufacturers will need to develop more aggressive contracting strategies to secure optimal market access for their medical benefit drugs. Shifting market dynamics, driven in part by the influx of lower cost biosimilars on the pharmacy benefit, will require pharma companies to […]
What Payers Want: Understanding Payer Preferences When Evaluating Therapies
Many manufacturers are interested in which factors can give them an edge on obtaining preferred coverage with payers. This is especially true given the increasing competition in saturated categories such as immunology, diabetes care and breast cancer. We scoured recent MMIT research to gain a better grasp on the factors that are top of mind […]
Market Access 101: Understanding the Basics
For many pharmaceutical companies, planning for commercialization only begins in earnest when a drug has been submitted for FDA approval—which is far too late. Ideally, a company’s commercial and market access teams should be fully functional long before the approval stage, as many decisions must be made in the early phases of the drug development […]
Is Lab Data the Secret Weapon for More Efficient Clinical Trials?
According to the National Institutes of Health (NIH), approximately 80% of research studies fail to meet their enrollment goals within the stated timeframes. Recruitment and trial design challenges can prolong the timeline for phase III studies, driving up costs and delaying market entry. While many sponsors use aggregated data and predictive analytics to improve the […]
Payers and PBMs Are Excluding Cancer Drugs at a Growing Rate. How Can Manufacturers Prepare?
With rebates now a common pharma practice, and generics and biosimilars launching in oncology, payer management of once-untouchable cancer drugs is growing. As the FDA continues to approve a large number of cancer drugs, resulting in increased competition in various tumor types, and spending on these agents continues to rise, PBM and payer formularies are […]
Integrating Lab Data Into Your Physician Engagement Strategy: 5 Key Benefits
This article was originally published in BioPharma Dive. In the competitive pharma marketplace, physician engagement plays a critical role in a drug manufacturer’s commercialization strategy. However, before manufacturers can promote a new therapy directly to providers, they must first determine which physicians treat the relevant patient population. By investing in timely lab data, manufacturers can […]
Manufacturers: Are You Familiar With Payers’ Genetic Testing Coverage Procedures?
As researchers continue to identify specific genetic markers within different diseases, more and more treatments targeting those markers are launching. In fact, more than 77,000 genetic tests currently are available. They can identify, for example, what type of breast cancer or non-small cell lung cancer a patient has. Some can determine a person’s risk for […]